OKYO Pharma Ltd. (OKYO) is scheduled to present an update on the development of its lead drug candidate, Urcosimod, for the treatment of neuropathic corneal pain at the BIO International Convention, taking place from June 16 to 19, 2025.
Neuropathic corneal pain is a condition that causes severe pain and sensitivity of the eyes, face, or head. The exact cause of neuropathic corneal pain is unknown, but it is thought to result from nerve damage to the cornea combined with inflammation. Currently, there are no FDA-approved drugs to treat this condition.
For comments and feedback contact: editorial@rttnews.com
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.